Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer

CN Johnstone; A Chand; TL Putoczki; M Ernst

Journal article

Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer

CN Johnstone, A Chand, TL Putoczki, M Ernst

Cytokine and Growth Factor Reviews | ELSEVIER SCI LTD | Published : 2015

DOI: 10.1016/j.cytogfr.2015.07.015

Abstract

Interleukin (IL)-11 is a member of the IL-6 family of cytokines that is defined by the shared use of the GP130 signal transducing receptor subunit. In addition of its long recognized activities as a hemopoietic growth factor, IL-11 has an emerging role in epithelial cancer biology. Through the activation of the GP130-Janus kinase signaling cascade and associated transcription factor STAT3, IL-11 can confer many of the tumor intrinsic 'hallmark' capabilities to neoplastic cells, if they express the ligand-specific IL-11Rα receptor subunit. Accordingly, IL-11 signaling has recently been identified as a rate-limiting step for the growth tumors arising from the mucosa of the gastrointestinal tra..

View full abstract

University of Melbourne Researchers

Tracy Putoczki Author

Related Projects (3)

ESTABLISHING AND VALIDATING A NEW THERPAUETIC TARGET FOR COLON AND STOMACH CANCER

Cancers of the stomach and the colon are a major health burden. One of the central signaling molecules that drives these cancers is called S..

TARGETING COLON CANCER WITH JAK INHIBITORS

Colorectal cancer (CRC) is the 3rd most common cancer worldwide. 85% of CRC arises from mutations in the Wnt signalling pathway. We have sho..

IMPROVING TARGETED THERAPY FOR COLORECTAL CANCER

Colorectal cancer (CRC) is one of the most common causes of cancer-associated death in the world. We aim to understand why some CRC patients..

Grants

Awarded by National Science Foundation

Funding Acknowledgements

State Government Operational Infrastructure Support, and NHMRC grants 1008614 and 1080498 (to T.L. Putoczki) and 603122, 1064987, 1069024 and 1079257 (to M. Ernst) and WCR, formally AICR (to T.L. Putoczki) and the WEHI Dyson Centenary Fellowship (to T.L. Putoczki). The laboratory of M. Ernst also receives financial supported from Ludwig Cancer Research. M. Ernst and T.L. Putoczki are inventors of patents describing the use of IL-11 antagonists for the treatment of cancer. The authors have no additional relevant existing or perceived financial interest.